Zelapar and Labile affect - a phase IV clinical study of FDA data

Summary:

We study 179 people who take Zelapar (selegiline hydrochloride) or have Labile affect. No report of Labile affect is found in people who take Zelapar.

The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.

What is Zelapar?

Zelapar has active ingredients of selegiline hydrochloride. It is often used in parkinson's disease. eHealthMe is studying from 136 Zelapar users. Check the latest studies of Zelapar.

What is Labile Affect?

Labile affect (emotional incontinence refers to a neurologic disorder characterized by involuntary crying) is found to be associated with 5 drugs and 8 conditions by eHealthMe. Check the latest studies of Labile affect.

On Jul, 25, 2026

No report is found.

Do you take Zelapar and have Labile affect?

- Check whether Labile affect is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zelapar:

Zelapar (136 reports)

Browse all side effects of Zelapar:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Labile affect:

Labile affect

Browse all the conditions that are associated with Labile affect:

Labile affect

How the study uses the data?

The study uses data from the FDA. It is based on selegiline hydrochloride (the active ingredients of Zelapar) and Zelapar (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.